Development and validation of a dissolution test for meloxicam and pridinol mesylate from combined tablet formulation.
The association of meloxicam and pridinol is indicated for treating muscular contractures and low back pain. A dissolution test for the meloxicam-pridinol combined tablet formulation was developed and validated, using a suitable HPLC method for simultaneously quantitating both dissolved drugs. The optimized conditions include the use of USP apparatus 2 at a paddle rotation rate of 75 rpm and 900 ml of 50 mM phosphate buffer (pH= 7.5) as dissolution medium, at 37.0±0.5°. The test, which demonstrated to be robust against small changes in bath temperature, paddle rotation speed and pH of the dissolution medium, was applied to two different brands of tablets; the corresponding dissolution profiles were constructed and both brands showed to dissolve at least 75% of the drugs at the 45 min time point.
Vignaduzzo
S E
SE
Institute of Chemistry, Rosario (IQUIR, CONICET-UNR), Suipach 513, 52002LRK, Rosario, Argentine.
Castellano
P M
PM
Kaufman
T S
TS